Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: Association with mucoadhesion and efficient penetration of the sublingual barrier

Vaccine

Volumn 29, Issue 40, 2011, Pages 7080-7089

  Domm, William ^a   Brooks, Lauren ^a   Chung, Hung Li ^b   Feng, Changyong ^c   Bowers, William J ^a   Watson, Gene ^d   McGrath, James L ^b   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b University of Rochester   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Adenovirus; Antibody; Env; Herpes simplex virus; HIV 1; HSV; IgA; Mucosal; Saliva; Sublingual; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RECOMBINANT ADENOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG PENETRATION; FEMALE; GENE EXPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALIVA; VIRION; VIRUS ENVELOPE;

ADENOVIRIDAE; ADMINISTRATION, SUBLINGUAL; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VECTORS; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; SALIVA; VIRION;

EID: 80052315038     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.008     Document Type: Article

References (54)

1. Murrell W. Nitroglycerin as a remedy for angina pectoris. Lancet 1879, 1. 80-1, 113-5, 51-2, 225-7.
2. Goswami T., Jasti B., Li X. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst 2008, 25(5):449-484.
3. Frew A.J. Sublingual immunotherapy. N Engl J Med 2008, 358(May (21)):2259-2264.
4. Broide D.H. Immunomodulation of allergic disease. Annu Rev Med 2009, 60:279-291.
5. Durham S.R. Sublingual immunotherapy: what have we learnt from the 'big trials'?. Curr Opin Allergy Clin Immunol 2008, 8(December (6)):577-584.
6. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121(February (2)). 512-8 e2.
7. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118(August (2)):434-440.
8. Didier A., Malling H.J., Worm M., Horak F., Jager S., Montagut A., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120(December (6)):1338-1345.
9. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117(April (4)):802-809.
10. Cuburu N., Kweon M.N., Hervouet C., Cha H.R., Pang Y.Y., Holmgren J., et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009, 183(December (12)):7851-7859.
11. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25(December (51)):8598-8610.
12. Song J.H., Kim J.I., Kwon H.J., Shim D.H., Parajuli N., Cuburu N., et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 2009, 182(June (11)):6851-6860.
13. Huang C.F., Wu T.C., Chu Y.H., Hwang K.S., Wang C.C., Peng H.J. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand J Immunol 2008, 68(November (5)):502-510.
14. Zhang T., Hashizume T., Kurita-Ochiai T., Yamamoto M. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem Biophys Res Commun 2009, 390(December (3)):937-941.
15. Raghavan S., Ostberg A.K., Flach C.F., Ekman A., Blomquist M., Czerkinsky C., et al. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun 2010, 78(October (10)):4251-4260.
16. Hervouet C., Luci C., Cuburu N., Cremel M., Bekri S., Vimeux L., et al. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 2010, 28(August (34)):5582-5590.
17. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008, 105(February (5)):1644-1649.
18. Hennessy M., MacQueen K., McKirnan D.J., Buchbinder S., Judson F., Douglas J.M., et al. A factorial survey study to assess the acceptability of HIV vaccine trial designs. Control Clin Trials 1996, 17(June (3)):209-220.
19. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003, 77(September (18)):10078-10087.
20. Appledorn D.M., Aldhamen Y.A., Godbehere S., Seregin S.S., Amalfitano A. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity. Clin Vaccine Immunol 2011, 18(January (1)):150-160.
21. Duke C.M., Maguire C.A., Keefer M.C., Federoff H.J., Bowers W.J., Dewhurst S. HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine 2007, 25(October (42)):7410-7421.
22. Hocknell P.K., Wiley R.D., Wang X., Evans T.G., Bowers W.J., Hanke T., et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 2002, 76(June (11)):5565-5580.
23. Santos K., Duke C.M., Rodriguez-Colon S.M., Dakwar A., Fan S., Keefer M.C., et al. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine 2007, 25(February (9)):1634-1646.
24. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998, 95(March (5)):2509-2514.
25. Mattiacio J., Walter S., Brewer M., Domm W., Friedman A.E., Dewhurst S. Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env. Vaccine 2011, 29(March (14)):2637-2647.
26. Maguire C.A., Sapinoro R., Girgis N., Rodriguez-Colon S.M., Ramirez S.H., Williams J., et al. Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens. Vaccine 2006, 24(January (5)):671-682.
27. Desai P., Person S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol 1998, 72(September (9)):7563-7568.
28. Bowers W.J., Howard D.F., Brooks A.I., Halterman M.W., Federoff H.J. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Ther 2001, 8(January (2)):111-120.
29. Sims K., Ahmed Z., Read M.L., Cooper-Charles L., Gonzalez A.M., Fisher K.D., et al. In vitro evaluation of a 'stealth' adenoviral vector for targeted gene delivery to adult mammalian neurones. J Gene Med 2009, 11(April (4)):335-344.
30. Bindschadler M., McGrath J.L. Sheet migration by wounded monolayers as an emergent property of single-cell dynamics. J Cell Sci 2007, 120(March (Pt 5)):876-884.
31. van der Vaart A.W. Asymptotic statistics 1998, Cambridge University Press, Cambridge, U.K.
32. Sheludyakov V.D., Tkachev A.S., Sheludyakova S.V., Kozyukov V., Mironov V.F. Synthesis and properties of organic and organosilicon acyl isocyanates. J Gen Chem USSR 1977, 2061-2067.
33. Fan S., Maguire C.A., Ramirez S.H., Bradel-Tretheway B., Sapinoro R., Sui Z., et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005, 125(April (1)):23-33.
34. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005, 79(August (16)):10103-10107.
35. Stewart P.L., Burnett R.M., Cyrklaff M., Fuller S.D. Image reconstruction reveals the complex molecular organization of adenovirus. Cell 1991, 67(October (1)):145-154.
36. Grunewald K., Desai P., Winkler D.C., Heymann J.B., Belnap D.M., Baumeister W., et al. Three-dimensional structure of herpes simplex virus from cryo-electron tomography. Science 2003, 302(November (5649)):1396-1398.
37. Yura Y., Iga H., Terashima K., Yoshida H., Yanagawa T., Hayashi Y., et al. The role of epithelial cell differentiation in the expression of herpes simplex virus type 1 in normal human oral mucosa in culture. Arch Virol 1987, 92(1-2):41-53.
38. Sturn B., Schneweis K.E. Protective effect of an oral infection with herpes simplex virus type 1 against subsequent genital infection with herpes simplex virus type 2. Med Microbiol Immunol 1978, 165(July (2)):119-127.
39. Dawes C. The composition f human saliva secreted in response to a gustatory stimulus and to pilocaprine. J Physiol 1966, 183(March (2)):360-368.
40. Denny P.C., Denny P.A., Yim M.S. The effects of various secretagogues on the mucin content of pure submandibular salivas. J Dent Res 1987, 66(May (5)):1011-1015.
41. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001, 81(October (4)):1930-1937.
42. Lai S.K., Wang Y.Y., Hida K., Cone R., Hanes J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci USA 2010, 107(January (2)):598-603.
43. Hale B.D., Rendtorff R.C., Walker L.C., Roberts A.N. Epidemic herpetic stomatitis in an orphanage nursery. JAMA 1963, 183(March):1068-1072.
44. Buddingh G.J., Schrum D.I., Lanier J.C., Guidry D.J. Studies of the natural history of herpes simplex infections. Pediatrics 1953, 11(June (6)):595-610.
45. Malamud D., Davis C., Berthold P., Roth E., Friedman H. Human submandibular saliva aggregates HIV. AIDS Res Hum Retroviruses 1993, 9(July (7)):633-637.
46. Pawar D., Goyal A.K., Mangal S., Mishra N., Vaidya B., Tiwari S., et al. Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010, 12(June (2)):130-137.
47. Slutter B., Bal S., Keijzer C., Mallants R., Hagenaars N., Que I., et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010, 28(August (38)):6282-6291.
48. Park J.S., Oh Y.K., Kang M.J., Kim C.K. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol 2003, 70(August (4)):633-641.
49. Florindo H.F., Pandit S., Lacerda L., Goncalves L.M., Alpar H.O., Almeida A.J. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles. Biomaterials 2009, 30(February (5)):879-891.
50. Saint-Lu N., Tourdot S., Razafindratsita A., Mascarell L., Berjont N., Chabre H., et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009, 64(July (7)):1003-1013.
51. Bomsel M., Heyman M., Hocini H., Lagaye S., Belec L., Dupont C., et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9(August (2)):277-287.
52. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34(February (2)):269-280.
53. Renegar K.B., Jackson G.D., Mestecky J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J Immunol 1998, 160(February (3)):1219-1223.
54. Cho H.J., Kim J.Y., Lee Y., Kim J.M., Kim Y.B., Chun T., et al. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 2010, 28(March (14)):2598-2606.